RBC Capital Markets has started covering French drugmaker Sanofi with a “sector perform” rating, a neutral stance that signals the bank sees the company’s turnaround as credible but not yet compelling enough to chase. In a note to clients, RBC described Sanofi as a “show-me” story, meaning the company will need to prove its strategy with hard results before the stock gets a meaningful re-rating.
The timing is the key issue. RBC points to a “light catalyst calendar” through the rest of 2026, meaning there are few major events—such as late-stage trial readouts or regulatory decisions—that could force analysts to sharply revise their sales forecasts. For a company in the middle of a turnaround, that can leave the stock drifting until something concrete moves the needle.
What’s behind the ‘show-me’ label?
Sanofi’s turnaround effort is being led by CEO Belen Garijo, who has been trying to reset the company’s growth narrative after a string of high-profile drug-development setbacks. Those misses have weighed on investor confidence, and the company is now working to rebuild its pipeline and prove it can deliver new blockbusters.
But the immediate picture is still heavily dependent on Dupixent, Sanofi’s blockbuster inflammation drug. Dupixent, which treats conditions like eczema, asthma, and nasal polyps, has been a major growth driver for years. However, investors are increasingly looking ahead to the eventual loss of patent protection, which will open the door to cheaper biosimilar competition. That looming pressure is a big reason why Sanofi’s valuation has been under scrutiny.
RBC’s “sector perform” rating is essentially a hold. It suggests the bank thinks Sanofi’s shares are fairly valued given the mix of risks and opportunities. The “show-me” framing is a common one in the pharmaceutical sector, where companies often need to demonstrate that their pipelines can replace revenue from drugs that are losing exclusivity.
How big pharma stocks typically get re-rated
In the pharmaceutical industry, share prices often move when late-stage trial results or regulatory decisions land. A positive Phase 3 readout can add billions to a company’s market value overnight, because it makes future sales more certain. Conversely, a failed trial can wipe out a chunk of value just as quickly.
With a thin catalyst calendar, Sanofi investors may have to wait for those moments. The company’s next major data readouts or regulatory decisions could be months away, and in the meantime, the stock may trade more on broader market sentiment and general news flow.
This is a familiar pattern for large drugmakers. Many have faced the so-called “patent cliff,” where a cluster of drugs lose exclusivity in a short period, and the market waits to see whether the company can fill the gap with new products. Sanofi’s situation is not unique, but the stakes are high because Dupixent is such a large part of its revenue base.
What it means for investors
For everyday investors, the key takeaway is that Sanofi’s turnaround is a long-term story, not a quick win. The company is making progress, but the market wants to see more evidence before it rewards the stock with a higher valuation.
Investors should also be aware that “sector perform” ratings are not a call to buy or sell. They are a signal that the stock is likely to move in line with its sector over the next 12 months or so. That means Sanofi’s performance will probably be more tied to the overall health of the pharmaceutical industry than to company-specific news.
One thing to watch is how Sanofi manages its reliance on Dupixent. The company has been investing in other areas, including vaccines and oncology, but those efforts will take time to bear fruit. In the meantime, any updates on Dupixent’s sales trajectory or on pipeline progress could move the stock.
RBC’s note also highlights a broader theme in the sector: investors are increasingly focused on the durability of drug companies’ growth. With patent expirations looming for many blockbusters across the industry, the ability to innovate and bring new drugs to market is becoming a key differentiator.
For those considering Sanofi, the message is to be patient. The turnaround story is credible, but the proof will come in the data, not in promises. As always, it’s wise to consider how any single stock fits into a diversified portfolio, and to keep an eye on the company’s upcoming announcements.
In the meantime, investors might also look at how other drugmakers are navigating similar challenges. For example, Sandoz investors are seeking a post-2028 growth plan, a reminder that the industry is full of companies trying to define their next chapter. And while Sanofi’s situation is its own, the broader theme of patent cliffs and pipeline replenishment is one that affects many large pharma names.
RBC’s “show-me” stance is a fair summary of where Sanofi stands. The company has a credible plan, but the market will need to see results. Until then, the stock may remain in a holding pattern, waiting for the next catalyst to arrive.
